Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Subscribe To Our Newsletter & Stay Updated